Olaparib Benefits HR-Deficient TNBC and Platinum-Sensitive Ovarian Cancers
In a groundbreaking phase 2 clinical trial, researchers have demonstrated the efficacy of olaparib, a PARP inhibitor, in treating metastatic ...
In a groundbreaking phase 2 clinical trial, researchers have demonstrated the efficacy of olaparib, a PARP inhibitor, in treating metastatic ...
In a groundbreaking study poised to reshape the landscape of precision oncology, researchers have conducted the largest pan-cancer analysis focusing ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine